Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Astrazeneca Plc (AZN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 95,540,984
  • Shares Outstanding, K 2,532,900
  • Annual Sales, $ 22,465 M
  • Annual Income, $ 3,001 M
  • 36-Month Beta 0.60
  • Price/Sales 4.25
  • Price/Cash Flow 11.30
  • Price/Book 6.69

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate 0.44
  • Number of Estimates 2
  • High Estimate 0.46
  • Low Estimate 0.42
  • Prior Year 1.12
  • Growth Rate Est. (year over year) -60.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
36.88 +2.17%
on 09/06/18
39.01 -3.41%
on 08/30/18
-1.08 (-2.79%)
since 08/21/18
3-Month
34.38 +9.60%
on 06/28/18
39.76 -5.23%
on 08/09/18
+2.53 (+7.20%)
since 06/21/18
52-Week
31.99 +17.79%
on 12/06/17
39.76 -5.23%
on 08/09/18
+4.87 (+14.84%)
since 09/21/17

Most Recent Stories

More News
NVS vs. AZN: Which Stock Is the Better Value Option?

NVS vs. AZN: Which Stock Is the Better Value Option?

AZN : 37.68 (-0.11%)
NVS : 85.46 (-0.59%)
Merck or Pfizer: Which is the Better Large-Cap Pharma Stock?

In the Large-cap pharma sector, Merck (MRK) and Pfizer (PFE) are two of the biggest names.

AZN : 37.68 (-0.11%)
MRK : 71.10 (+0.45%)
PFE : 44.06 (+0.71%)
MKGAF : 101.5000 (+0.45%)
AstraZeneca's Fasenra Long-Term Asthma Study Data Positive

AstraZeneca's (AZN) asthma drug, Fasenra, maintains improvements achieved over first year of treatment in severe eosinophilic asthma patients for the next 56 weeks.

AZN : 37.68 (-0.11%)
TEVA : 24.36 (-1.89%)
AMGN : 205.10 (unch)
GSK : 40.30 (+1.08%)
Can Pfizer (PFE) Bank on Bavencio for Long-Term Growth?

Pfizer's (PFE) latest anti-PD-L1 immunotherapy, Bavencio, is being touted as a significant long-term top-line driver for the company.

AZN : 37.68 (-0.11%)
MRK : 71.10 (+0.45%)
PFE : 44.06 (+0.71%)
BMY : 62.25 (+0.81%)
FASENRA (benralizumab) Shows Consistent Safety and Sustained Efficacy in Long-Term Phase III BORA Trial in Severe Eosinophilic Asthma

--Data presented at the European Respiratory Society (ERS) International Congress 2018

AZN : 37.68 (-0.11%)
Is Artificial Intelligence the Next Big Thing in Biotech?

Artificial intelligence can drastically reduce the time taken to develop new life-saving drugs.

AZN : 37.68 (-0.11%)
JNJ : 142.88 (+0.63%)
NVS : 85.46 (-0.59%)
RHHBY : 30.6200 (+0.07%)
GSK : 40.30 (+1.08%)
PFE : 44.06 (+0.71%)
SNY : 43.55 (-1.36%)
Pharma Stock Roundup: AZN's Leukemia Drug Wins FDA Nod, MRK's Keytruda in Focus

Label expansion of Merck's (MRK) Keytruda and FDA approval of AstraZeneca's (AZN) leukemia drug grab headlines this week

AZN : 37.68 (-0.11%)
JNJ : 142.88 (+0.63%)
MRK : 71.10 (+0.45%)
LLY : 106.33 (+0.25%)
PFE : 44.06 (+0.71%)
GSK : 40.30 (+1.08%)
BMY : 62.25 (+0.81%)
Pharma/Biotech Stocks to Watch This Prostate Cancer Month

Here we highlight a few companies that are focused on developing treatments for prostate cancer.

AZN : 37.68 (-0.11%)
JNJ : 142.88 (+0.63%)
ECYT : 17.53 (-0.57%)
ABBV : 92.26 (-0.45%)
TSRO : 37.69 (-0.32%)
PFE : 44.06 (+0.71%)
SNY : 43.55 (-1.36%)
AstraZeneca's Lumoxiti Gets FDA Nod for Hairy Cell Leukemia

AstraZeneca's (AZN) rare blood cancer candidate receives approval from the FDA for relapsed or refractory hairy cell leukemia (HCL) in patients who have received at least two prior systemic therapies.

AZN : 37.68 (-0.11%)
MRK : 71.10 (+0.45%)
LLY : 106.33 (+0.25%)
RHHBY : 30.6200 (+0.07%)
Spectrum Pharma Includes First-Line NSCLC in Poziotinib Study

Spectrum Pharma (SPPI) amends poziotinib study protocol to include two cohorts to evaluate it in first-line lung cancer.

SPPI : 21.36 (-0.74%)
CATB : 0.84 (+1.20%)
AZN : 37.68 (-0.11%)
PCRX : 50.50 (-2.88%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade AZN with:

Business Summary

AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development,...

See More

Key Turning Points

2nd Resistance Point 37.97
1st Resistance Point 37.82
Last Price 37.68
1st Support Level 37.48
2nd Support Level 37.29

See More

52-Week High 39.76
Last Price 37.68
Fibonacci 61.8% 36.79
Fibonacci 50% 35.88
Fibonacci 38.2% 34.96
52-Week Low 31.99

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar